Freeze-thaw is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-07-30. Where a claim depends on a specific study, the study is described rather than over-claimed.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
Identification in laboratories relies on reversed-phase liquid chromatography coupled with tandem mass spectrometry, with product-ion spectra compared against a certified reference standard. High-resolution mass spectrometry supplies accurate mass confirmation, and peptide mapping after enzymatic digestion separates melanotan II from closely related analogues. Quantitation of seized material is complicated by unknown counter-ions and residual trifluoroacetate left from purification. Immunoassays raised against alpha-melanocyte-stimulating hormone can cross-react, so chromatographic confirmation is normally required. Urinary detection windows are short, and reported limits of detection differ substantially between laboratories.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic cyclic heptapeptide | Analog of alpha-MSH with an internal lactam bridge |
| Molecular weight | Approximately 1024 daltons | Free base value; salt forms differ |
| Appearance | White to off-white powder | Usually supplied as a lyophilized solid |
| Solubility | Freely soluble in water | Poorly soluble in nonpolar solvents |
| Typical storage | −20 °C, dry, protected from light | Repeated freeze-thaw cycles degrade peptides |
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
Verification of a purchased sample requires documentation linking a batch to a certificate of analysis, and that document should be read for the methods used rather than the headline purity figure. A single chromatographic percentage does not establish identity. Independent laboratories can perform identity and content assays, but no such test establishes that a product is suitable for human use. Claims about efficacy rest largely on small, early studies rather than on replicated controlled trials, and that gap remains open.
Identity testing for a cyclic peptide of this size usually relies on reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The mass spectrum confirms molecular weight, while the chromatographic trace indicates the proportion of related impurities. Tandem mass spectrometry can provide sequence-level information when fragmentation data are compared against a reference standard. Nuclear magnetic resonance is sometimes used to confirm the lactam bridge, although it requires more material and greater operator expertise than routine chromatographic methods.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
The app's operator suggested in court documents pertaining to its lawsuit to overturn the order that the retaliation was also for a ticket reservation prank waged by some users of the video platform that depressed attendance for a campaign rally he held in Tulsa, Oklahoma, that June. The executive order was blocked by federal courts in two separate cases on grounds that the sanctions likely violated IEEPA's informational materials exemption (under the Berman Amendment) and First Amendment protections applying to users of the apps. In February 2026, the Supreme Court held that the IEEPA did not authorize the president to set tariffs in Learning Resources, Inc. v. Trump. This decision reversed the tariffs implemented by Trump under IEEPA during his second term. Consequently, U.S. Customs established a new process—the Consolidated Administration & Processing of Entries (CAPE) system—to refund importers for voided IEEPA duties.
=== Hemolytic Anemia === Broad category of anemias where red blood cells are destroyed faster than they can be replaced, prompting the bone marrow to increase red blood cell production and the release of immature red blood cells into the bloodstream. Reticulocytosis provides strong suspicion of hemolysis when present along with many other markers like elevations in lactate dehydrogenase and unconjugated bilirubin or a decrease in haptoglobin.
=== Approaches === In keeping with the performance and mass range of available mass spectrometers, two approaches are used for characterizing proteins. In the first, intact proteins are ionized by either of the two techniques described above, and then introduced to a mass analyzer. This approach is referred to as "top-down" strategy of protein analysis as it involves starting with the whole mass and then pulling it apart. The top-down approach however is mostly limited to low-throughput single-protein studies due to issues involved in handling whole proteins, their heterogeneity and the complexity of their analyses. In the second approach, referred to as the "bottom-up" MS, proteins are enzymatically digested into smaller peptides using a protease such as trypsin. Subsequently, these peptides are introduced into the mass spectrometer and identified by peptide mass fingerprinting or tandem mass spectrometry. Hence, this approach uses identification at the peptide level to infer the existence of proteins pieced back together with de novo repeat detection. The smaller and more uniform fragments are easier to analyze than intact proteins and can be also determined with high accuracy, this "bottom-up" approach is therefore the preferred method of studies in proteomics. A further approach that is beginning to be useful is the intermediate "middle-down" approach in which proteolytic peptides larger than the typical tryptic peptides are analyzed.
Harrison also introduced commercial vapour-compression refrigeration to breweries and meat-packing houses, and by 1861, a dozen of his systems were in operation. He later entered the debate of how to compete against the American advantage of unrefrigerated beef sales to the United Kingdom. In 1873 he prepared the sailing ship Norfolk for an experimental beef shipment to the United Kingdom, which used a cold room system instead of a refrigeration system. The venture was a failure as the ice was consumed faster than expected.
Sources: en.wikipedia.org
Nitazenes are a chemically defined class of substances derived from the parent compound nitazene. Nitazenes were developed in the second half of the 1950s by the Swiss company Ciba AG as pain-relieving agents. They are important as centrally active, selective μ-opioid receptor agonists. The high potency of fentanyl (in humans) is matched by a few nitazenes and surpassed by etonitazene and isotonitazene. Nitazenes were never included in the pharmacopoeia of human or veterinary medicine and have not been approved for human use. Since 2019, highly potent nitazenes have proliferated as ″new synthetic opioids″ in the North American and European narcotics markets and as such have become a formative component of the opioid epidemic in the United States. Overdoses of nitazene opioids have led to several hundred documented fatalities.
== History == At the initiative of Sudameris, a French-Italian bank that served markets in South America, which had accumulated a large coffee surplus in its warehouses, Nestlé began developing a new instant coffee product in 1932 to use the surplus of beans. The large supply of surplus came from the lowered coffee prices in Brazil which resulted from the Wall Street Crash of 1929. Max Morgenthaler led the development project of the instant coffee product, which initially used spray drying to create the product from liquid coffee. Nestlé introduced the new product under the brand name "Nescafé" on April 1, 1938. It became an American staple during World War II.
A statistical test that is used to find out if there is a real difference between the means (averages) of two different groups. It is sometimes used to see if there is a significant difference in response to treatment between groups in a clinical trial. (NCI)
=== Prosecution === In his opening statement, prosecutor Brian Leveson portrayed the Wests as sadistic sex-obsessed murderers, terming the bodies discovered at Cromwell Street and Midland Road "secrets more terrible than words can express ... [The victims'] last moments on earth were as objects of the sexual depravity of this woman and her husband." He pointed out that Fred had been incarcerated when Charmaine was killed, claimed that Fred and Rose had each learned from their mistake in allowing Owens to live, and said that the gag on victim Thérèse Siegenthaler evinced a "feminine" touch—a scarf tied in a bow. Leveson promised to demonstrate Rose's controlling and sexually sadistic character, as well as her efforts to deflect suspicion about the disappearance of their victims. Prosecution witnesses included Cromwell Street lodgers, victims' relatives, Rose's mother, Daisy, and sister, Glenys, and surviving victims including Kathryn Halliday (a former lover of Fred and Rose), Owens, Anne Marie and a "Miss A" (who had been sexually assaulted at age 14 by Fred and Rose in 1977 and who described Rose as the more aggressive perpetrator of the two). Neighbours described Charmaine's 1971 disappearance while Fred was imprisoned and Rose's casual indifference to Heather's disappearance. Rose's counsel, Dick Ferguson, tried to discredit prosecution witnesses as either having financially exploited their connection to the case or being motivated by grudges.
subphylum Anthozoa Ehrenberg, 1834 class Hexacorallia Haeckel, 1896 — stony corals class Octocorallia Haeckel, 1866 — soft corals and sea fans subphylum Endocnidozoa Zrzavý & Hypša, 2003 — parasites class Myxozoa Grassé, 1970 class Polypodiozoa Raikova, 1994 subphylum Medusozoa Petersen, 1979 class Cubozoa Werner, 1973 — box jellies class Hydrozoa Owen, 1843 — hydrozoans (fire corals, hydroids, hydroid jellyfishes, siphonophores...) class Scyphozoa Goette, 1887 — "true" jellyfishes class Staurozoa Marques & Collins, 2004 — stalked jellyfishes
Sources: en.wikipedia.org
It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.
Melanotan-1, also called afamelanotide, is a shorter linear analog with a different amino acid sequence and no lactam ring. It has been evaluated in formal clinical programs, while melanotan-2 has not. The two are distinct molecules and are not interchangeable.
No. Bremelanotide is a related but distinct cyclic peptide that reached approved status for one specific clinical indication. Melanotan-2 is a separate molecule with its own sequence and properties. Shared ancestry in the melanocortin family does not make them the same substance.
Regulatory treatment varies by country. In the United States, the European Union and Australia it is an unapproved drug and its sale is restricted, while some other jurisdictions list it as prescription-only or controlled. The applicable rules depend on the country of import.